Which has better earnings & valuation, CAPR or ODTX?

Odyssey Therapeutics has lower revenue, but higher earnings than Capricor Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Capricor Therapeutics $22.27M 10.13 -$105.04M -$2.32 N/A Odyssey Therapeutics N/A N/A N/A N/A N/A

Is CAPR or ODTX more profitable?

Odyssey Therapeutics' return on equity of 0.00% beat Capricor Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Capricor Therapeutics N/A -59.27% -48.65% Odyssey Therapeutics N/A N/A N/A

Does the media refer more to CAPR or ODTX?

In the previous week, Capricor Therapeutics had 43 more articles in the media than Odyssey Therapeutics. MarketBeat recorded 50 mentions for Capricor Therapeutics and 7 mentions for Odyssey Therapeutics. Odyssey Therapeutics' average media sentiment score of 0.38 beat Capricor Therapeutics' score of -0.06 indicating that Odyssey Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Capricor Therapeutics 0 Very Positive mention(s) 2 Positive mention(s) 42 Neutral mention(s) 3 Negative mention(s) 3 Very Negative mention(s) Neutral Odyssey Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is CAPR or AVTX more profitable?

Avalo Therapeutics' return on equity of -58.03% beat Capricor Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Capricor Therapeutics N/A -59.27% -48.65% Avalo Therapeutics N/A -58.03% -48.22%

Does the media favor CAPR or AVTX?

In the previous week, Capricor Therapeutics had 39 more articles in the media than Avalo Therapeutics. MarketBeat recorded 50 mentions for Capricor Therapeutics and 11 mentions for Avalo Therapeutics. Capricor Therapeutics' average media sentiment score of -0.06 beat Avalo Therapeutics' score of -0.21 indicating that Capricor Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Capricor Therapeutics 0 Very Positive mention(s) 2 Positive mention(s) 42 Neutral mention(s) 3 Negative mention(s) 3 Very Negative mention(s) Neutral Avalo Therapeutics 2 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 4 Negative mention(s) 0 Very Negative mention(s) Neutral

Is CAPR or JBIO more profitable?

Jade Biosciences' return on equity of -51.34% beat Capricor Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Capricor Therapeutics N/A -59.27% -48.65% Jade Biosciences N/A -51.34% -47.32%

Does the media favor CAPR or JBIO?

In the previous week, Capricor Therapeutics had 46 more articles in the media than Jade Biosciences. MarketBeat recorded 50 mentions for Capricor Therapeutics and 4 mentions for Jade Biosciences. Jade Biosciences' average media sentiment score of 1.12 beat Capricor Therapeutics' score of -0.06 indicating that Jade Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Capricor Therapeutics 0 Very Positive mention(s) 2 Positive mention(s) 42 Neutral mention(s) 3 Negative mention(s) 3 Very Negative mention(s) Neutral Jade Biosciences 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is JANX or CAPR more profitable?

Janux Therapeutics' return on equity of -11.89% beat Capricor Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Janux Therapeutics N/A -11.89% -11.13% Capricor Therapeutics N/A -59.27% -48.65%

Does the media refer more to JANX or CAPR?

In the previous week, Capricor Therapeutics had 47 more articles in the media than Janux Therapeutics. MarketBeat recorded 50 mentions for Capricor Therapeutics and 3 mentions for Janux Therapeutics. Capricor Therapeutics' average media sentiment score of -0.06 beat Janux Therapeutics' score of -0.74 indicating that Capricor Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Janux Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Negative Capricor Therapeutics 0 Very Positive mention(s) 2 Positive mention(s) 42 Neutral mention(s) 3 Negative mention(s) 3 Very Negative mention(s) Neutral

Is CAPR or OMER more profitable?

Capricor Therapeutics' return on equity of -59.27% beat Omeros' return on equity. Company Net Margins Return on Equity Return on Assets Capricor Therapeutics N/A -59.27% -48.65% Omeros N/A -102.16% 64.87%

Does the media refer more to CAPR or OMER?

In the previous week, Capricor Therapeutics had 45 more articles in the media than Omeros. MarketBeat recorded 50 mentions for Capricor Therapeutics and 5 mentions for Omeros. Omeros' average media sentiment score of 0.36 beat Capricor Therapeutics' score of -0.06 indicating that Omeros is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Capricor Therapeutics 0 Very Positive mention(s) 2 Positive mention(s) 42 Neutral mention(s) 3 Negative mention(s) 3 Very Negative mention(s) Neutral Omeros 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Capricor Therapeutics (CAPR) Competitors

$3.90 -0.20 (-4.77%)

As of 10:48 AM Eastern

Compare

CAPR vs. ODTX, AVTX, JBIO, JANX, and OMER

Should you buy Capricor Therapeutics stock or one of its competitors? MarketBeat compares Capricor Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Capricor Therapeutics include Odyssey Therapeutics (ODTX), Avalo Therapeutics (AVTX), Jade Biosciences (JBIO), Janux Therapeutics (JANX), and Omeros (OMER). These companies are all part of the "biotechnology" industry.

How does Capricor Therapeutics compare to Odyssey Therapeutics?

Capricor Therapeutics (NASDAQ:CAPR) and Odyssey Therapeutics (NASDAQ:ODTX) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, media sentiment, institutional ownership, profitability, valuation, dividends, earnings and risk.

Capricor Therapeutics presently has a consensus target price of $29.15, suggesting a potential upside of 648.40%. Odyssey Therapeutics has a consensus target price of $33.00, suggesting a potential upside of 53.63%. Given Capricor Therapeutics' higher probable upside, equities analysts plainly believe Capricor Therapeutics is more favorable than Odyssey Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Capricor Therapeutics	1 Sell rating(s)	10 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.91
Odyssey Therapeutics	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.83

In the previous week, Capricor Therapeutics had 43 more articles in the media than Odyssey Therapeutics. MarketBeat recorded 50 mentions for Capricor Therapeutics and 7 mentions for Odyssey Therapeutics. Odyssey Therapeutics' average media sentiment score of 0.38 beat Capricor Therapeutics' score of -0.06 indicating that Odyssey Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Capricor Therapeutics	0 Very Positive mention(s)	2 Positive mention(s)	42 Neutral mention(s)	3 Negative mention(s)	3 Very Negative mention(s)	Neutral
Odyssey Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Odyssey Therapeutics has lower revenue, but higher earnings than Capricor Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Capricor Therapeutics	$22.27M	10.13	-$105.04M	-$2.32	N/A
Odyssey Therapeutics	N/A	N/A	N/A	N/A	N/A

Odyssey Therapeutics' return on equity of 0.00% beat Capricor Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Capricor Therapeutics	N/A	-59.27%	-48.65%
Odyssey Therapeutics	N/A	N/A	N/A

21.7% of Capricor Therapeutics shares are owned by institutional investors. 9.2% of Capricor Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Capricor Therapeutics and Odyssey Therapeutics tied by winning 5 of the 10 factors compared between the two stocks.

How does Capricor Therapeutics compare to Avalo Therapeutics?

Capricor Therapeutics (NASDAQ:CAPR) and Avalo Therapeutics (NASDAQ:AVTX) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, risk, media sentiment, dividends, institutional ownership, analyst recommendations, earnings and valuation.

Capricor Therapeutics presently has a consensus price target of $29.15, indicating a potential upside of 648.40%. Avalo Therapeutics has a consensus price target of $45.10, indicating a potential upside of 140.03%. Given Capricor Therapeutics' higher possible upside, equities analysts clearly believe Capricor Therapeutics is more favorable than Avalo Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Capricor Therapeutics	1 Sell rating(s)	10 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.91
Avalo Therapeutics	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.86

21.7% of Capricor Therapeutics shares are held by institutional investors. Comparatively, 87.1% of Avalo Therapeutics shares are held by institutional investors. 9.2% of Capricor Therapeutics shares are held by insiders. Comparatively, 4.5% of Avalo Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Capricor Therapeutics has a beta of 0.54, indicating that its stock price is 46% less volatile than the broader market. Comparatively, Avalo Therapeutics has a beta of 0.8, indicating that its stock price is 20% less volatile than the broader market.

In the previous week, Capricor Therapeutics had 39 more articles in the media than Avalo Therapeutics. MarketBeat recorded 50 mentions for Capricor Therapeutics and 11 mentions for Avalo Therapeutics. Capricor Therapeutics' average media sentiment score of -0.06 beat Avalo Therapeutics' score of -0.21 indicating that Capricor Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Capricor Therapeutics	0 Very Positive mention(s)	2 Positive mention(s)	42 Neutral mention(s)	3 Negative mention(s)	3 Very Negative mention(s)	Neutral
Avalo Therapeutics	2 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	4 Negative mention(s)	0 Very Negative mention(s)	Neutral

Avalo Therapeutics' return on equity of -58.03% beat Capricor Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Capricor Therapeutics	N/A	-59.27%	-48.65%
Avalo Therapeutics	N/A	-58.03%	-48.22%

Avalo Therapeutics has lower revenue, but higher earnings than Capricor Therapeutics. Avalo Therapeutics is trading at a lower price-to-earnings ratio than Capricor Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Capricor Therapeutics	$22.27M	10.13	-$105.04M	-$2.32	N/A
Avalo Therapeutics	$60K	16,794.23	-$78.26M	-$4.37	N/A

Summary

Avalo Therapeutics beats Capricor Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Capricor Therapeutics compare to Jade Biosciences?

Capricor Therapeutics (NASDAQ:CAPR) and Jade Biosciences (NASDAQ:JBIO) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, dividends, media sentiment, analyst recommendations, institutional ownership, earnings, risk and profitability.

In the previous week, Capricor Therapeutics had 46 more articles in the media than Jade Biosciences. MarketBeat recorded 50 mentions for Capricor Therapeutics and 4 mentions for Jade Biosciences. Jade Biosciences' average media sentiment score of 1.12 beat Capricor Therapeutics' score of -0.06 indicating that Jade Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Capricor Therapeutics	0 Very Positive mention(s)	2 Positive mention(s)	42 Neutral mention(s)	3 Negative mention(s)	3 Very Negative mention(s)	Neutral
Jade Biosciences	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

21.7% of Capricor Therapeutics shares are owned by institutional investors. 9.2% of Capricor Therapeutics shares are owned by insiders. Comparatively, 23.1% of Jade Biosciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Capricor Therapeutics presently has a consensus price target of $29.15, suggesting a potential upside of 648.40%. Jade Biosciences has a consensus price target of $51.57, suggesting a potential upside of 134.69%. Given Capricor Therapeutics' higher possible upside, equities research analysts clearly believe Capricor Therapeutics is more favorable than Jade Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Capricor Therapeutics	1 Sell rating(s)	10 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.91
Jade Biosciences	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	2.90

Jade Biosciences' return on equity of -51.34% beat Capricor Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Capricor Therapeutics	N/A	-59.27%	-48.65%
Jade Biosciences	N/A	-51.34%	-47.32%

Capricor Therapeutics has a beta of 0.54, suggesting that its share price is 46% less volatile than the broader market. Comparatively, Jade Biosciences has a beta of 1.49, suggesting that its share price is 49% more volatile than the broader market.

Capricor Therapeutics has higher revenue and earnings than Jade Biosciences. Jade Biosciences is trading at a lower price-to-earnings ratio than Capricor Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Capricor Therapeutics	$22.27M	10.13	-$105.04M	-$2.32	N/A
Jade Biosciences	N/A	N/A	-$127.41M	-$2.02	N/A

Summary

Jade Biosciences beats Capricor Therapeutics on 9 of the 15 factors compared between the two stocks.

How does Capricor Therapeutics compare to Janux Therapeutics?

Janux Therapeutics (NASDAQ:JANX) and Capricor Therapeutics (NASDAQ:CAPR) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, risk, media sentiment, analyst recommendations, earnings, valuation, dividends and institutional ownership.

75.4% of Janux Therapeutics shares are held by institutional investors. Comparatively, 21.7% of Capricor Therapeutics shares are held by institutional investors. 7.9% of Janux Therapeutics shares are held by insiders. Comparatively, 9.2% of Capricor Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Janux Therapeutics has a beta of 2.5, indicating that its share price is 150% more volatile than the broader market. Comparatively, Capricor Therapeutics has a beta of 0.54, indicating that its share price is 46% less volatile than the broader market.

In the previous week, Capricor Therapeutics had 47 more articles in the media than Janux Therapeutics. MarketBeat recorded 50 mentions for Capricor Therapeutics and 3 mentions for Janux Therapeutics. Capricor Therapeutics' average media sentiment score of -0.06 beat Janux Therapeutics' score of -0.74 indicating that Capricor Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Janux Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Negative
Capricor Therapeutics	0 Very Positive mention(s)	2 Positive mention(s)	42 Neutral mention(s)	3 Negative mention(s)	3 Very Negative mention(s)	Neutral

Janux Therapeutics presently has a consensus target price of $37.58, indicating a potential upside of 130.66%. Capricor Therapeutics has a consensus target price of $29.15, indicating a potential upside of 648.40%. Given Capricor Therapeutics' higher probable upside, analysts clearly believe Capricor Therapeutics is more favorable than Janux Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Janux Therapeutics	2 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.50
Capricor Therapeutics	1 Sell rating(s)	10 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.91

Janux Therapeutics' return on equity of -11.89% beat Capricor Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Janux Therapeutics	N/A	-11.89%	-11.13%
Capricor Therapeutics	N/A	-59.27%	-48.65%

Capricor Therapeutics has higher revenue and earnings than Janux Therapeutics. Janux Therapeutics is trading at a lower price-to-earnings ratio than Capricor Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Janux Therapeutics	$10M	99.62	-$113.62M	-$1.64	N/A
Capricor Therapeutics	$22.27M	10.13	-$105.04M	-$2.32	N/A

Summary

Janux Therapeutics beats Capricor Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Capricor Therapeutics compare to Omeros?

Capricor Therapeutics (NASDAQ:CAPR) and Omeros (NASDAQ:OMER) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, risk, media sentiment, earnings, dividends, analyst recommendations, institutional ownership and valuation.

Capricor Therapeutics' return on equity of -59.27% beat Omeros' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Capricor Therapeutics	N/A	-59.27%	-48.65%
Omeros	N/A	-102.16%	64.87%

Omeros has lower revenue, but higher earnings than Capricor Therapeutics. Capricor Therapeutics is trading at a lower price-to-earnings ratio than Omeros, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Capricor Therapeutics	$22.27M	10.13	-$105.04M	-$2.32	N/A
Omeros	N/A	N/A	-$3.35M	$0.70	18.90

Capricor Therapeutics has a beta of 0.54, meaning that its share price is 46% less volatile than the broader market. Comparatively, Omeros has a beta of 2.54, meaning that its share price is 154% more volatile than the broader market.

Capricor Therapeutics currently has a consensus target price of $29.15, indicating a potential upside of 648.40%. Omeros has a consensus target price of $38.00, indicating a potential upside of 187.27%. Given Capricor Therapeutics' higher probable upside, analysts clearly believe Capricor Therapeutics is more favorable than Omeros.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Capricor Therapeutics	1 Sell rating(s)	10 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.91
Omeros	0 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.67

21.7% of Capricor Therapeutics shares are held by institutional investors. Comparatively, 48.8% of Omeros shares are held by institutional investors. 9.2% of Capricor Therapeutics shares are held by insiders. Comparatively, 10.5% of Omeros shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, Capricor Therapeutics had 45 more articles in the media than Omeros. MarketBeat recorded 50 mentions for Capricor Therapeutics and 5 mentions for Omeros. Omeros' average media sentiment score of 0.36 beat Capricor Therapeutics' score of -0.06 indicating that Omeros is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Capricor Therapeutics	0 Very Positive mention(s)	2 Positive mention(s)	42 Neutral mention(s)	3 Negative mention(s)	3 Very Negative mention(s)	Neutral
Omeros	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Omeros beats Capricor Therapeutics on 11 of the 15 factors compared between the two stocks.

Get Capricor Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CAPR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CAPR vs. The Competition

Export

Metric	Capricor Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$225.27M	$3.71B	$7.02B	$12.96B
Dividend Yield	N/A	3.76%	2.58%	10.20%
P/E Ratio	-1.68	9.07	269.90	24.97
Price / Sales	10.13	1,294.66	659.13	107.89
Price / Cash	N/A	44.95	28.89	37.44
Price / Book	0.70	17.71	11.29	6.44
Net Income	-$105.04M	-$13.25M	$3.45B	$347.50M
7 Day Performance	-7.26%	5.42%	3.56%	3.82%
1 Month Performance	-81.89%	-1.71%	-0.57%	-0.37%
1 Year Performance	-57.06%	61.70%	77.67%	23.81%

Capricor Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CAPR Capricor Therapeutics	2.6335 of 5 stars	$3.90 -4.8%	$29.15 +648.4%	-54.9%	$225.27M	$22.27M	N/A	101	Trending News Upcoming Earnings
ODTX Odyssey Therapeutics	3.8408 of 5 stars	$19.96 +10.1%	$32.00 +60.3%	N/A	$958.70M	$1.06M	N/A	N/A	News Coverage Earnings Report Analyst Forecast
AVTX Avalo Therapeutics	2.3414 of 5 stars	$18.53 +2.7%	$45.80 +147.2%	+105.2%	$954.90M	$60K	N/A	40	Earnings Report Analyst Forecast Gap Up
JBIO Jade Biosciences	3.2935 of 5 stars	$21.35 +11.5%	$51.57 +141.6%	+193.2%	$945.24M	N/A	N/A	20	Positive News Earnings Report Gap Up
JANX Janux Therapeutics	2.6874 of 5 stars	$15.96 +4.2%	$38.08 +138.6%	-30.6%	$934.28M	$10M	N/A	30	Positive News Earnings Report Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CAPR) was last updated on 8/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Capricor Therapeutics (CAPR) Competitors

CAPR vs. ODTX, AVTX, JBIO, JANX, and OMER

How does Capricor Therapeutics compare to Odyssey Therapeutics?

Summary

How does Capricor Therapeutics compare to Avalo Therapeutics?

Summary

How does Capricor Therapeutics compare to Jade Biosciences?

Summary

How does Capricor Therapeutics compare to Janux Therapeutics?

Summary

How does Capricor Therapeutics compare to Omeros?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CAPR vs. The Competition

Capricor Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Capricor Therapeutics (CAPR) Competitors

CAPR vs. ODTX, AVTX, JBIO, JANX, and OMER

How does Capricor Therapeutics compare to Odyssey Therapeutics?

Do analysts prefer CAPR or ODTX?

Does the media refer more to CAPR or ODTX?

Which has better earnings & valuation, CAPR or ODTX?

Is CAPR or ODTX more profitable?

Do institutionals and insiders have more ownership in CAPR or ODTX?

Summary

How does Capricor Therapeutics compare to Avalo Therapeutics?

Do analysts rate CAPR or AVTX?

Do insiders and institutionals believe in CAPR or AVTX?

Which has more risk & volatility, CAPR or AVTX?

Does the media favor CAPR or AVTX?

Is CAPR or AVTX more profitable?

Which has preferable valuation and earnings, CAPR or AVTX?

Summary

How does Capricor Therapeutics compare to Jade Biosciences?

Does the media favor CAPR or JBIO?

Do institutionals and insiders have more ownership in CAPR or JBIO?

Do analysts prefer CAPR or JBIO?

Is CAPR or JBIO more profitable?

Which has more risk & volatility, CAPR or JBIO?

Which has stronger earnings & valuation, CAPR or JBIO?

Summary

How does Capricor Therapeutics compare to Janux Therapeutics?

Do insiders and institutionals hold more shares of JANX or CAPR?

Which has more volatility & risk, JANX or CAPR?

Does the media refer more to JANX or CAPR?

Do analysts prefer JANX or CAPR?

Is JANX or CAPR more profitable?

Which has higher earnings and valuation, JANX or CAPR?

Summary

How does Capricor Therapeutics compare to Omeros?

Is CAPR or OMER more profitable?

Which has preferable earnings and valuation, CAPR or OMER?

Which has more volatility & risk, CAPR or OMER?

Do analysts prefer CAPR or OMER?

Do insiders and institutionals believe in CAPR or OMER?

Does the media refer more to CAPR or OMER?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CAPR vs. The Competition

Capricor Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools